Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 12/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 4/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 0.84 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.84 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29359496 | 1.00 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL29599389 | 1.00 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL12265125 | 1.00 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL13276118 | 1.00 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL10529743 | 1.00 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL31060879 | 1.00 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL10608249 | 1.00 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL14829269 | 1.00 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL21033426 | 1.00 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL10529777 | 1.00 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207689-A1 | THE TREATMENT OF HEARING LOSS | AUCKLAND UNISERVICES LIMITED | 2011-08-25 | — | — | US | claimed |
| US-20140336142-A1 | Method For Treatment Of Macular Degeneration By Modulating P2Y12 or P2X7 Receptors | MITCHELL CLAIRE (US) | 2014-11-13 | — | — | US | disclosed |
| EP-2701719-A1 | METHOD FOR TREATMENT OF MACULAR DEGENERATION BY MODULATING P2Y12 OR P2X7 RECEPTORS | Mitchell, Claire (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20130338145-A1 | Method for Mediating Dopamine Receptor-Driven Reacidification of Lysosomal pH | MITCHELL CLAIRE H (US) | 2013-12-19 | — | — | US | disclosed |
| WO-2012149285-A1 | METHOD FOR TREATMENT OF MACULAR DEGENERATION BY MODULATING P2Y12 OR P2X7 RECEPTORS | MITCHELL CLAIRE (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20110207689-A1 | THE TREATMENT OF HEARING LOSS | AUCKLAND UNISERVICES LIMITED | 2011-08-25 | — | — | US | disclosed |
| US-20110207689-A1 | THE TREATMENT OF HEARING LOSS | AUCKLAND UNISERVICES LIMITED | 2011-08-25 | — | — | US | disclosed |
| US-20090247483-A1 | Method for Treatment of Macular Degeneration | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-10-01 | — | — | US | disclosed |
| EP-2089016-A2 | METHOD FOR TREATMENT OF MACULAR DEGENERATION | The Trustees of the University of Pennsylvania (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008042399-A9 | METHOD FOR TREATMENT OF MACULAR DEGENERATION | UNIV PENNSYLVANIA (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008042399-A2 | METHOD FOR TREATMENT OF MACULAR DEGENERATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207689-A1 | THE TREATMENT OF HEARING LOSS | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA3 3/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.